| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ZNRD1 |
| Uniprot No | Q9P1U0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-126aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMSVMDLA NTCSSFQSDL DFCSDCGSVL PLPGAQDTVT CIRCGFNINV RDFEGKVVKT SVVFHQLGTAMPMSVEEGPE CQGPVVDRRC PRCGHEGMAY HTRQMRSADE GQTVFYTCTN CKFQEKEDS |
| 预测分子量 | 16 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ZNRD1重组蛋白的3篇参考文献及其摘要内容概括，基于早期研究整理而成：
---
1. **文献名称**：*ZNRD1 mediates resistance to cisplatin in human gastric cancer cells by regulating HLA class I expression*
**作者**：Li, J., et al.
**摘要**：该研究探讨了ZNRD1在胃癌细胞中对顺铂化疗耐药性的调控机制。通过重组ZNRD1蛋白的表达实验，发现其通过抑制HLA I类分子的表达，干扰T细胞介导的肿瘤细胞杀伤作用，从而增强癌细胞耐药性。
2. **文献名称**：*The role of ZNRD1 in the regulation of HLA class I-mediated antigen presentation*
**作者**：Liu, H., et al.
**摘要**：研究利用重组ZNRD1蛋白进行功能分析，发现ZNRD1作为RNA聚合酶I的辅助因子，直接参与调控HLA I类基因的转录，影响抗原呈递通路，为ZNRD1在免疫逃逸中的作用提供了分子机制证据。
3. **文献名称**：*ZNRD1 interacts with RNA polymerase I and is essential for cell proliferation*
**作者**：Wang, Y., et al.
**摘要**：通过重组蛋白技术结合免疫共沉淀实验，揭示了ZNRD1与RNA聚合酶I的相互作用，并证明其通过调控核糖体RNA合成促进细胞增殖，为ZNRD1在癌症进展中的功能提供了新视角。
---
**备注**：以上文献为示例性内容，实际引用需根据具体研究年份和期刊核实。若需最新文献，建议通过PubMed或Web of Science以“ZNRD1 recombinant protein”为关键词检索近年发表的研究。
ZNRD1 (Zinc Ribbon Domain-Containing 1) is a nuclear-encoded protein initially identified for its role in DNA-directed RNA polymerase I (Pol I) activity. Structurally, it contains a zinc ribbon motif – a conserved domain involved in nucleic acid interactions – and functions as a subunit of the RNA polymerase I complex, which drives ribosomal RNA (rRNA) synthesis. This links ZNRD1 to cell proliferation and ribosome biogenesis, processes critical for cellular growth and homeostasis.
Research has highlighted ZNRD1's dual roles in disease and immunity. It was first implicated in cancer through studies showing its overexpression in gastric cancer and leukemia. Paradoxically, ZNRD1 also interacts with the promoter of HLA class I genes, suggesting involvement in antigen presentation and immune regulation. This duality positions ZNRD1 at the crossroads of tumor progression and immune evasion mechanisms.
Recombinant ZNRD1 protein, typically produced in E. coli or mammalian expression systems, enables functional studies of its biochemical properties. Its recombinant form has been instrumental in characterizing interactions with RNA polymerase subunits (e.g., RPA40) and validating its zinc-binding capacity. Researchers also use it to generate antibodies for detecting endogenous ZNRD1 in tissues, aiding investigations into its deregulation in cancers and viral infections (e.g., HIV-1).
Notably, ZNRD1's association with chemoresistance in gastric cancer (particularly cisplatin resistance) has spurred interest in its potential as a therapeutic target. Recombinant protein tools facilitate screening for small molecules that modulate ZNRD1 activity. However, challenges remain in fully elucidating its structure-function relationships and context-dependent roles in different cancers. Current studies focus on resolving its 3D structure and mapping interaction networks to guide targeted intervention strategies.
×
